Authors: Jade Parker, Editor
Could you give us a brief overview of the data you recently presented at the ESMO 2017 Congress (8–12th September, Madrid, Spain) exploring the efficacy and safety of ABP 980 compared with trastuzumab in patients with HER2 positive-early breast cancer?
- Phase 3 data on our biosimilar trastuzumab candidate, ABP 980, was presented for the first time during a poster discussion at the ESMO 2017 Congress.
- The study evaluated the efficacy and safety of ABP 980, a trastuzumab biosimilar, compared with the originator product in patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer, including neoadjuvant and adjuvant use.
What were the primary endpoints of this study?Restricted Content / Members Only
Restricted Content / Members Only